Design and studies of novel 5-substituted alkynylpyrimidine nucleosides as potent inhibitors of mycobacteria

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 7012-7017

  Rai, Dinesh ^a   Johar, Monika ^a   Manning, Tracey ^a   Agrawal, B ^a   Kunimoto, Dennis Y ^a   Kumar, Rakesh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYLURIDINE; 5 (2 PHENYLETHYNYL) 2' DEOXYCYTIDINE; 5 (2 PHENYLETHYNYL) 2' DEOXYURIDINE; 5 DECYNYL 2' DEOXYCYTIDINE; 5 DECYNYL 2' DEOXYURIDINE; 5 DODECYNYL 2' DEOXYCYTIDINE; 5 DODECYNYL 2' DEOXYURIDINE; 5 ETHYNYLDEOXYURIDINE; 5 HEPTYNYL 2' DEOXYCYTIDINE; 5 HEPTYNYL 2' DEOXYURIDINE; 5 PENTYNYL 2' DEOXYCYTIDINE; 5 PENTYNYL 2' DEOXYURIDINE; 5 PENTYNYLURIDINE; 5 PROPYNYL 2' DEOXYCYTIDINE; 5 PROPYNYL 2' DEOXYURIDINE; 5 TETRADECYNYL 2' DEOXYURIDINE; ALKYNE; ALKYNYL GROUP; ANTIMYCOBACTERIAL AGENT; BICYCLO COMPOUND; COPPER; DEOXYCYTIDINE; DEOXYRIBOSE; DEOXYURIDINE DERIVATIVE; IODINE DERIVATIVE; PALLADIUM; PYRIMIDINE NUCLEOSIDE; RIBOSE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DERIVATIVE;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; CATALYSIS; CHEMICAL REACTION; CONTROLLED STUDY; CYCLIZATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; DRUG DESIGN; HUMANS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS; PYRIMIDINE NUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27444434251     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058167w     Document Type: Article

References (29)

1. Pilheu, J. A. Tuberculosis 2000: Problems and Solutions. Int. J. Tuberc. Lung Dis. 1998, 2, 696-703.
2. Raviglione, M. C.; Snider, D. E.; Kochi, A. Global Epidemiology of Tuberculosis. Morbidity and Mortality of a Worldwide Epidemic. J. Am. Med. Assoc. 1995, 273, 220-226.
3. (a) Willcox, P. A. Drug-Resistant Tuberculosis. Curr. Opin. Pulm. Med. 2000, 6, 198-202.
4. (b) Méndez, A. P.; Raviglione, M. C.; Laszlo, A.; Binkin, N.; Rieder, H. L.; Bustreo, F.; Cohn, D. L.; Lambregts-van Weezenbeek, C. S. B.; Kim, S. J.; Chaulet, P.; Nunn, P. Global Surveillance for Antituberculosis-Drug Resistance, 1994-1997. World Health Organization. International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Engl. J. Med. 1998, 338, 1641-1649.
5. Peloquin, C. A.; Berning, S. E. Infections Caused by Mycobacterium tuberculosis. Ann. Pharmacother. 1994, 28, 72-84.
6. (a) Murray, J. F. Tuberculosis and HIV Infection: A Global Perspective. Respiration 1998, 65, 335-342.
7. (b) Gordin, F. M.; Nelson, E. T.; Matts, J. P.; Cohn, D. L. J., Benator, E. D.; Besch, C. L.; Crane, L. R.; Sampson, J. H.; Bragg, P. S.; El-Sadr, W. The Impact of HIV Infection on Drug-Resistant Tuberculosis. Am. J. Respir. Crit. Care Med. 1996, 154, 1478-1483.
8. (c) Moss, A. R.; Alland, D.; Telzak, E.; Hewlett, D., Jr.; Sharp, V.; Chiliade, P.; LaBombardi, V.; Kabus, D.; Hanna, B.; Palumbo, L.; Brudney, K.; Weltman, A.; Stoeckle, K.; Chirgwin, K.; Simberkoff, M.; Moghazeh, S.; Eisner, W.; Lutfey, M.; Kreiswirth, B. A City-Wide Outbreak of a Multiple-Drug-Resistant Strain of Mycobacterium Tuberculosis in New York. Int. J. Tuberc. Lung Dis. 1997, 1, 115-121.
9. (d) National Survey of Tuberculosis in England and Wales. Communicable Dis. Rep. Weekly 1998, 8, 209-212.
10. Pozniak, A. Mycobacterial Diseases and HIV. J. HIV Ther. 2002, 7, 13-16.
11. Colditz, G. A.; Brewer, T. F.; Berkey, C. S.; Wilson, M. E.; Burdick, E.; Fineberg, H. V.; Mosteller, F. Efficacy of BCG Vaccine in the Prevention of Tuberculosis. Meta-Analysis of the Published Literature. JAMA, J. Am. Med. Assoc. 1994, 271, 698-702.
12. (a) Koehler, C. S. W. Consumption the great killer. Modern Drug Discovery 2002, 47-49.
13. (b) Guerrero, A. Nosocomial Transmission of M. bovis Resistant to 11 Drugs in People with Advanced HIV-1 Infection. Lancet 1997, 350, 1738-1742.
14. Inderlied, C. B.; Kemper, C. A.; Bermudez, L. E. The Mycobacterium avium complex. Clin. Microbiol. Rev. 1993, 6, 266-310.
15. Falkinham, J. O., III. Epidemiology of Infection by Nontuberculous Mycobacteria. Clin. Microbiol. Rev. 1996, 9, 177-215.
16. Dautzenberg, B. Clinical Trials in Mycobacterium avium Therapy: Lessons To Take Home. Res. Microbiol. 1994, 145, 197-206.
17. Ellner, J. J.; Goldberger, M. J.; Parenti, D. M. Mycobacterium avium Infection and AIDS: A Therapeutic Dilemma in Rapid Evolution. J. Infect. Dis. 1991, 163, 1326-1335.
18. Johar, M.; Manning, T.; Kunimoto, D. Y.; Kumar, R. In vitro Anti-Mycobacterial Activity of 5-Substituted Pyrimidine Nucleosides. Bioorg. Med Chem., in press.
19. (a) Fillastre, J. P.; Godin, M.; Legallicier, B.; Chretien, P.; Bidault, R.; Gillotin, C.; Wooton, R.; Posner, J.; Peck, R. W. Pharmacokinetics of Netivudine, a Potent Anti-Varicella Zoster Virus Drug, in Patients with Renal Impairment. J. Antimicrob. Chemother. 1996, 37, 965-974.
20. (b) Beres, J.; Bentrude, W. G.; Balzarini, J.; De Clercq, E.; Otvos, L. Synthesis and Antitumor and Antiviral Properties of 5-Alkyl-2′- deoxyuridines, 3′,5′-Cyclic Monophosphates, and Neutral Cyclic Triesters. J. Med. Chem. 1986, 29, 494-499.
21. Herdewijn, P. A. M. M. 5-Substituted-2′-deoxyuridines as Anti-HSV-1 Agents: Synthesis and Structure Activity Relationships. Antiviral Chem. Chemother. 1994, 5, 131-146.
22. (d) Vincent, P.; Beaucourt, J. P.; Pichat, L. Alcynyl-5 desoxy-2′-uridines par Couplages d'Organozinciques Acetyleniques avec l'Iodo-5O-3′,5′-bis(trimethylsilyl)desoxyuridine. Catalyzes Par des Complexes Organopalladies et de Nickel (Alkynyl-5-desoxy-2′-uridines by Coupling of Organozinc Acetylenes with Iodo-5O-3′,5′- bis(trimethylsilyl)desoxyuridine. Catalyses by Complex Organopalladium and Nickel) Tetrahedron Lett. 1981, 22, 945-947.
23. De Clercq, E.; Descamps, J.; Balzarini, J.; Giziewicz, J.; Barr, P. J.; Robins, M. J. Nucleic Acid Related Compounds. 40. Synthesis and Biological Activities of 5-Alkynyluracil Nucleosides. J. Med. Chem. 1983, 26, 661-666.
24. McGuigan, C.; Yarnold, C. J.; Jones, G.; Velazquez, S.; Barucki, H.; Brancale, A.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J. Potent and Selective Inhibition of Varicella-Zoster Virus (VZV) by Nucleoside Analogues with an Unusual Bicyclic Base. J. Med. Chem. 1999, 42, 4479-4484.
25. (a) Franzblau, S. G.; Witzig, R. S.; McLaughlin, J. C.; Torres, P.; Madico, G.; Hernandez, A.; Degnan, M. T.; Cook, M. B.; Quenzer, V. K.; Ferguson, R. M.; Gilman, R. H. Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay. J. Clin. Microbiol. 1998, 36, 362-366.
26. (b) Collins, L.; Franzblau, S.G. Microplate Alamar Blue Assay versus BACTEC 460 System for High-Throughput Screening of Compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents. Chemother. 1997, 41, 1004-1009.
27. Ryan, A. J.; Gray, N. M.; Lowe, P. N.; Chung, C. Effect of Detergent on Promiscuous Inhibitors. J. Med. Chem. 2003, 46, 3448-3451.
28. Neugebauer, J. M. Detergents: An Overview. Methods Enzymol. 1990, 182, 239-153.
29. Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S. V.; Eiglmeier, K.; Gas, S.; Barry, C. E., III; Tekala, F.; Badcock, K.; Bashman, D.; Brown, D.; Chillingworth, T. R.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; Mclean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M. A.; Rajandream, M.-A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; Whitehead S.; Barrell, B. G. Deciphering the Biology of Mycobacterium tuberculosis from the Complete Genome Sequence. Nature 1998, 393, 537-544.